Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study

Annals of Intensive Care

Table 1 Patients’ characteristics

Parameter	ACLF	NLF	p
Number of patients	n = 8	n = 11
Age [years]	59 (46–68)	61 (55–75)	0.31
Gender	Males: 6	Males: 8	1.0
Gender	Females: 2	Females: 3	1.0
Weight [kg]	78 (60–81)	77 (55–86)	0.97
Height [cm]	175 (166–180)	175 (170–184)	0.49
APACHE II	30 (25–40)	32 (20–38)	0.97
SOFA	16 (15–19)	14 (11–19)	0.44
Blood flow rate [mL*h⁻¹]	100 (100–200)	100 (100–200)	0.84
Dialysate rate [mL*h⁻¹]	2000 (2000–2750)	2000 (2000–2000)	1.0
Ultrafiltrate [mL*h⁻¹]	25 (0–138)	150 (50–200)	0.17
Dialysate dose [mlkg⁻¹h⁻¹]	31 (23–37)	26 (23–40)	0.90
Patients receiving norepinephrine ≥ 0.01 µgkg⁻¹min⁻¹	88%	73%	0.60
PT [%]	50 (29–61)	87 (74–103)	0.001
Bilirubin [mg/dL]	7.4 (4.3–18.7)	2.1 (0.4–8.3)	0.05
Antithrombin [%]	48 (22–54)	71 (56–90)	0.004

ACLF acute-on-chronic liver failure due to liver cirrhosis, NLF patients without liver failure, APACHE II Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment Score, PT prothrombin time, ns not statistically significant, data are given as median and quartiles